Please try another search
For the fiscal year ended 31 March 2022, KAINOS Laboratories, Inc. revenues increased 8% to Y4.61B. Net income increased 23% to Y512.3M. Revenues reflect Products Sale increase of 8% to Y3.97B, Goods Sale increase of 13% to Y641.2M. Net income benefited from SP Val. Loss Inv. Sec decrease of 88% to Y4.7M (expense), Research & Devel. decrease of 15% to Y144.9M (expense), NOP Exchange Gain increase from Y7M to Y14.8M (income).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 1146.72 | 1138 | 1159.39 | 1170.62 |
Gross Profit | 556.24 | 604.2 | 588.64 | 658.37 |
Operating Income | 80.95 | 219.83 | 162.16 | 278.65 |
Net Income | 54.54 | 156.59 | 107.99 | 193.21 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 7571.52 | 7142.05 | 7176.28 | 7023.92 |
Total Liabilities | 2371.38 | 2250.11 | 2276.11 | 2237.88 |
Total Equity | 5200.13 | 4891.94 | 4900.17 | 4786.05 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 12 Months | 0 Months | 6 Months | 0 Months |
Cash From Operating Activities | 604.36 | 180.87 | ||
Cash From Investing Activities | -141.19 | -48.84 | ||
Cash From Financing Activities | -31.25 | -104.87 | ||
Net Change in Cash | 433.02 | 27.18 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review